Does TrumpRx's Price Talk Match Patient Savings?

The Trump administration's TrumpRx platform has been live for more than six months, but a new AMCP survey suggests health plans and PBMs remain skeptical that it's translating into real patient savings.

In Part 1 of his video interview with Pharmaceutical Commerce, Adam Colborn, JD, vice president of government affairs at the Academy of Managed Care Pharmacy (AMCP), broke down the survey's top-line findings, including that a majority of the 59 managed care professionals surveyed disagreed or strongly disagreed that TrumpRx offers patients the lowest available price for their medications.

In Part 2, Colborn unpacks what that skepticism actually signals. He notes patients already have an established range of affordability resources, from insurance benefits to manufacturer savings programs to pharmacy discount cards, and that many generics are inexpensive enough to fill at cash price regardless of channel. He also points out that a number of products featured on TrumpRx already face generic competition that undercuts the platform's advertised price, a dynamic he says isn't reflected in the headline savings figures. Combined with a lack of available usage data this early in the program, Colborn argues the finding is less a verdict on real-world value than a timing issue, describing the current headline number as " more messaging than true data."

Still, Colborn sees a potential upside that could outlast the messaging debate: a public benchmark price gives health plans and PBMs a new number to negotiate against. He points to GLP-1s as an early example, where the TrumpRx price landed well below other cash prices insurers had been tracking, giving PBMs a fresh target to beat in their own benefit design.

Watch part one of his interview with PC:

1. Health Plans, PBMs Wary of TrumpRx Impact on Patients